CEN Biotech, Inc.

OTC: CENBF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Windsor, ONCIK 0001653821Reports USD

#905 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ 17GM —SS 18

v0.1 · 25/100 weight · pillars only

↑ 3-yr revenue growth, Piotroski F · ↓ market scale, workforce scale

Methodology →

Revenue TTM

$619.8k

Rev growth YoY (TTM)

-54.9%

Net income (FY)

-$18.9M

Employees

Market cap

$6.5k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$626.9k$626.9k2021

Net income-$18.9M-$18.9M2021

Operating income-$19.0M-$19.0M2021

Total assets$8.4M$8.4M2021

Liabilities$10.1M$10.1M2021

Equity-$1.7M-$1.7M2021

Revenue trend

FY2016 – FY2021 · USD

$2.3k

FY16

FY17

FY21

$626.9k

FY21

Revenue by segment

Filed disclosures · FY2021

By product

Digital100%

Growth0%

By geography

Not disclosed.

The read

CEN Biotech, Inc. booked $626.9k in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -3015.6% net margin.

Peers · Healthcare

Bloomios, Inc.——Xsovt Brands, Inc.——Praxsyn Corporation——Entia Biosciences, Inc.——

Key facts

CEOBrian S. Payne

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersWindsor, ON

ExchangeOTC: CENBF

Employees4

IPO date2020-05-04

Latest filings

8-K2023-03-29 10-Q2022-11-14 8-K2022-09-16 8-K2022-09-07 8-K2022-08-31 10-Q2022-08-22 8-K2022-07-20 8-K2022-05-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.